182 related articles for article (PubMed ID: 30276213)
1. MultiParametric Magnetic Resonance Imaging-Based Nomogram for Predicting Prostate Cancer and Clinically Significant Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Huang C; Song G; Wang H; Ji G; Li J; Chen Y; Fan Y; Fang D; Xiong G; Xin Z; Zhou L
Biomed Res Int; 2018; 2018():6368309. PubMed ID: 30276213
[TBL] [Abstract][Full Text] [Related]
2. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
[No Abstract] [Full Text] [Related]
3. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
4. Nomogram predicting prostate cancer in patients with negative prebiopsy multiparametric magnetic resonance.
Chen M; Wang R; Zhang T; Zhang X; Wan Y; Fu X
Future Oncol; 2022 Apr; 18(12):1473-1483. PubMed ID: 35105154
[TBL] [Abstract][Full Text] [Related]
5. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
6. [Development of a Chinese nomogram based on muti-parametric magnetic resonance for predicting the probability of prostate cancer in patients after initial negative biopsy].
Huang C; Ji GJ; Song G; Wang H; Chen YK; Zhou LQ
Zhonghua Yi Xue Za Zhi; 2018 Jan; 98(2):132-135. PubMed ID: 29343039
[No Abstract] [Full Text] [Related]
7. A Novel Prediction Tool Based on Multiparametric Magnetic Resonance Imaging to Determine the Biopsy Strategy for Clinically Significant Prostate Cancer in Patients with PSA Levels Less than 50 ng/ml.
He BM; Shi ZK; Li HS; Lin HZ; Yang QS; Lu JP; Sun YH; Wang HF
Ann Surg Oncol; 2020 Apr; 27(4):1284-1295. PubMed ID: 31848822
[TBL] [Abstract][Full Text] [Related]
8. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
9. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
11. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
Siddiqui MR; Li EV; Kumar SKSR; Busza A; Lin JS; Mahenthiran AK; Aguiar JA; Shah PV; Ansbro B; Rich JM; Moataz SAS; Keeter MK; Mai Q; Mi X; Tosoian JJ; Schaeffer EM; Patel HD; Ross AE
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):588-595. PubMed ID: 36973367
[TBL] [Abstract][Full Text] [Related]
12. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.
Truong M; Wang B; Gordetsky JB; Nix JW; Frye TP; Messing EM; Thomas JV; Feng C; Rais-Bahrami S
Cancer; 2018 Jan; 124(2):278-285. PubMed ID: 28976544
[TBL] [Abstract][Full Text] [Related]
14. How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies.
Borque-Fernando Á; Esteban LM; Celma A; Roche S; Planas J; Regis L; de Torres I; Semidey ME; Trilla E; Morote J
World J Urol; 2020 Jun; 38(6):1481-1491. PubMed ID: 31506748
[TBL] [Abstract][Full Text] [Related]
15. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series.
Barletta F; Stabile A; Mazzone E; Brembilla G; Sorce G; Pellegrino F; Scuderi S; Cannoletta D; Cirulli GO; Cucchiara V; Gandaglia G; De Cobelli F; Montorsi F; Briganti A
Urol Oncol; 2022 Mar; 40(3):103.e17-103.e24. PubMed ID: 34688534
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
[TBL] [Abstract][Full Text] [Related]
17. A nomogram for prediction of prostate cancer on multi-core biopsy using age, serum prostate-specific antigen, prostate volume and digital rectal examination in Singapore.
Lee A; Lim J; Gao X; Liu L; Chia SJ
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e348-e355. PubMed ID: 27641069
[TBL] [Abstract][Full Text] [Related]
18. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
[TBL] [Abstract][Full Text] [Related]
19. Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy.
Cormio L; Cindolo L; Troiano F; Marchioni M; Di Fino G; Mancini V; Falagario U; Selvaggio O; Sanguedolce F; Fortunato F; Schips L; Carrieri G
Front Oncol; 2018; 8():438. PubMed ID: 30386737
[TBL] [Abstract][Full Text] [Related]
20. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]